# MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma

> **NCT00504205** · NA · TERMINATED · sponsor: **Astex Pharmaceuticals, Inc.** · enrollment: 30 (estimated)

## Conditions studied

- Lymphoma
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** multitargeted receptor tyrosine kinase inhibitor MP470
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study
- **PROCEDURE:** positron emission tomography

## Key facts

- **NCT ID:** NCT00504205
- **Lead sponsor:** Astex Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-05
- **Primary completion:** 2008-12
- **Final completion:** 2010-03
- **Target enrollment:** 30 (ESTIMATED)
- **Why stopped:** Withdrawn as trial was never activated by SuperGen
- **Last updated:** 2013-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00504205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00504205, "MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00504205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*